Cholangiocarcinoma is the second most common primary liver cancer. Its incidence is low in
the Western world but is rising globally. Surgery, chemotherapy and radiation therapy have …

Cholangiocarcinoma (CCA) is the second most common primary liver cancer and
associated with a dismal prognosis due to the lack of an efficient systemic therapy. In …

Advanced intrahepatic cholangiocarcinoma (ICC) has a dismal prognosis. Here, we report
the efficacy and safety of combining toripalimab, lenvatinib, and gemcitabine plus oxaliplatin …

Background: Immunotherapy has recently been incorporated into the spectrum of biliary tract
cancer (BTC) treatment. The identification of predictive response biomarkers is essential in …

Cholangiocarcinoma is characterized by a poor prognosis with limited treatment and
management options. Chemotherapy using gemcitabine with cisplatin is the only available …

Intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver cancer and
causes major economic and health burdens throughout the world. Although the incidence of …

Cholangiocarcinoma (CCA) is a highly heterogeneous malignancy originating from the
epithelial system of the bile ducts, and its incidence in recent years is steadily increasing …

Ordinary chronic pancreatitis is a well-known risk factor for pancreatic cancer, whereas such
an association with autoimmune pancreatitis (AIP) is widely debated. Due to the rarity of the …

Systemic treatments (eg, chemotherapy and targeted therapies) have limited efficacy for
patients with locally advanced–unresectable–and metastatic cholangiocarcinoma (CCA) …

Cholangiocarcinoma, the second most common liver malignancy, after hepatocarcinoma is
highly aggressive and usually diagnosed in advanced cases. In the era of personalized …